Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 255-460-7 | CAS number: 41611-76-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 24 September 1997 to 18 November 1997
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- When comparing to the OECD TG 407 (1995 version), the following deviations were reported: - sensory reactivity to stimuli and functional observations were not conducted - gross necropsy of testes was not performed - histopathological examinations were not performed on all the organs listed in the OECD TG.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1995
- Deviations:
- no
- Principles of method if other than guideline:
- Reinblau RLW Tr. was administered by oral gavage to male and female SD rats for 28 days at dose levels of 0, 8, 40, 200, and 1000 mg/kg to assess its toxicity and reversibility.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 1,4-bis[(2-ethyl-6-methylphenyl)amino]anthraquinone
- EC Number:
- 255-460-7
- EC Name:
- 1,4-bis[(2-ethyl-6-methylphenyl)amino]anthraquinone
- Cas Number:
- 41611-76-1
- Molecular formula:
- C32H30N2O2
- IUPAC Name:
- 1,4-bis[(2-ethyl-6-methylphenyl)amino]-9,10-dihydroanthracene-9,10-dione
- Details on test material:
- Reinblau RLW Tr. (CAS No. 41611-76-1, Lot No. 25C, Purity: 99.7%) was provided by Bayer Co., Ltd. and used in this study.
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: n/a
- Stability and homogeneity of the test material in the vehicle/solvent under test conditions (e.g. in the exposure medium) and during storage: the stability of the lot used in this study was confirmed but the Sponsor using IR analysis
- Stability in the medium, i.e. sensitivity of the test material to hydrolysis and/or photolysis: n/a
- Solubility and stability of the test material in the solvent/vehicle and the exposure medium: The stability and homogeneity of the test substance in the dosing formulations were confirmed between 0.4 and 100 mg/mL for 8 days in a refrigerator before the start of dosing.
- Reactivity of the test material with the incubation material used (e.g. plastic ware): n/a
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing (e.g. warming, grinding): n/a
- Preliminary purification step (if any): n/a
- Final concentration of a dissolved solid, stock liquid or gel: n/a
- Final preparation of a solid (e.g. stock crystals ground to fine powder using a mortar and pestle): n/a
FORM AS APPLIED IN THE TEST (if different from that of starting material) n/a
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Remarks:
- Crj: CD(SD) IGS
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles Liver Laboratories Japan Ltd. on September 24, 1997
- Females (if applicable) nulliparous and non-pregnant: yes; 48 females; 48 males.
- Age at study initiation: 5 weeks
- Weight at study initiation:146 g to 184 g for males and 119 g to 146 g for females.
- Fasting period before study: none
- Housing: polycarbonate cages (265W x 426D x 200H mm, Tokiwa Kagaku Kikai Co., Ltd.) with sterilized hardwood chip for experimental animals (Beta chip, Charles River Laboratories Japan Ltd.). After grouping, two animals were housed in a cage, which was placed on stainless steels racks (Tokiwa Kagaku Kikai Co., Ltd.), and the location of the cages was rotated once a week. Replaced once a week
- Diet (e.g. ad libitum): pellet diet ad libitum (MF, Oriental Yeast Co., Ltd.)
- Water (e.g. ad libitum): ad libitum, tap water passed through 5 µm filter and irradiated with UV light. Replaced once a week.
- Acclimation period: 13 days.
DETAILS OF FOOD AND WATER QUALITY: it was confirmed that the contaminants such as residual pesticides in the diet and bedding were meet the specifications of the standard operating procedure (SOP) of the test facility. In addition, the tap water was periodically analyzed based on the Water Supply Act, and was confirmed to meet the specification of the SOP of the test facility.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2°C (intended value)
- Humidity (%): 55±15%(intended value)
- Air changes (per hr):ventilation was about 12 times per hour
- Photoperiod (hrs dark / hrs light):12/12 (light from 7:00 to 19:00).
IN-LIFE DATES: From: 24 September 1997 To: 4 November 1997.
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- Oral route was selected according to the guideline.
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- CMC-Na solutions
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: The dosing volume was set at 10 mL/kg, and the individual dose volume was calculated on the basis of the most recent body weight.
VEHICLE
- Justification for use and choice of vehicle (if other than water): n/a
- Concentration in vehicle: 0.5% (test item suspended with motor and agate)
- Amount of vehicle (if gavage): n/a
- Lot/batch no. (if required): Iwai Chemicals Company Ltd.; Lot Nos. 121208 and 100709
- Purity:n/a - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The stability and homogeneity for 8 days of the test substance in the dosing formulations at 0.4 and 100 mg/mL were confirmed by the HPLC method.
The dosing formulations of initial preparation were analyzed and confirmed that the mean concentrations were within the nominal concentration ±10%. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily in the morning
Doses / concentrationsopen allclose all
- Dose / conc.:
- 8 mg/kg bw/day (nominal)
- Dose / conc.:
- 40 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Control + 200 + 1000 mg/kg bw/day: 12 / sex (incl. 6/sex recovery animals).
8 and 40 mg/kg bw/day: 6 / sex. - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: From the results of a preliminary study, the highest dose in this study was set at 1000 mg/kg, and then, doses of 200, 40, and 8 mg/kg were also set by common ratio of 4.
- Rationale for animal assignment (if not random): random
- Fasting period before blood sampling for clinical biochemistry: no
- Rationale for selecting satellite groups: control and high dose groups
- Post-exposure recovery period in satellite groups: 14 days
- Section schedule rationale (if not random): not applicable
- Dose range finding studies: In a preliminary 2-week repeated dose study (dose level: 0, 100, 500, and 1000 mg/kg bw/day; 3 males and 3 females per group), there were no changes attributable to the test substance treatment in clinical sign, body weight, haematology, organ weight, and necropsy.
- Other: none
Examinations
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS: Yes
- Time schedule: All animals were observed twice a day (before and after dosing) during the dosing period, and once in the morning during the other periods.
BODY WEIGHT: Yes
- Time schedule for examinations: once a week.
FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
-All feeders in each cages (including diet) were weighed using an electric balance once a week, and mean daily food consumption of each animal was calculated.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: on the scheduled necropsy day (days 29 or 43).
- Anaesthetic used for blood collection: Yes (sodium thiopental)
- Animals fasted: No
- How many animals: all animals
- Parameters checked in table [7.5.1/1] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: on the scheduled necropsy day (days 29 or 43).
- Animals fasted: No
- How many animals: all animals
- Parameters checked in table [7.5.1/1] were examined.
PLASMA/SERUM HORMONES/LIPIDS: No
URINALYSIS: Yes
- Time schedule for collection of urine: day 24
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: No
- Parameters checked in table [7.5.1/1] were examined.
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No
OTHER: n/a - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 7.5.1/2)
HISTOPATHOLOGY: Yes (see table 7.5.1/2)
At the results of the examination, since there were no changes suspected to be treatment-related, histopathological examination was not performed in the other groups necropsied at the end of the treatment period and all groups necropsied at the end of the recovery period. - Optional endpoint(s):
- Optional endpoints: No
- Statistics:
- Numerical data were analyzed statistically by the multiple comparison tests.
Numerical data were analyzed statistically by the multiple comparison tests. First, the data were tested by Bartlett’s test for homogeneity of variance. When the variance was homogeneous, one-way analysis of variance (ANOVA) was employed, and when the variance was heterogeneous, the Kruskal-Wallis test was performed. When there was a significant difference among the groups, the Dunnett test or the Dunnett-type multiple comparison test was applied. Categorical data were tested by X test (a*b). When there was a significant difference among the groups, Armitage’s X test was applied to compare between the control group and each dose group.
Statistical analysis was performed on the items listed below. The analysis was not performed on the data obtained in the clinical observation, necropsy, and histopathological examination.
Multiple comparison tests: Xtest:
Body weight, food consumption, hematology, blood chemistry, organ weight
Urinalysis (pH, protein, glucose, ketones, bilirubin, occult blood, urobilinogen)
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no abnormalities in any groups including the control group.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The body weight of animals in the test substance-treated groups was comparable to that in the control group.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The food consumption of animals in the test substance-treated groups was comparable to that in the control group.
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no abnormalities attributable to the test substance treatment at the end of the treatment or recovery periods.
Low values of hemoglobin concentration and hematocrit value were noted in males in the 200 mg/kg bw/day group, and shortening of APTT was noted in females in the 200 mg/kg bw/day group at the end of the recovery period; however, these changes were not considered to be treatment-related because similar changes were not noted at the end of the treatment period or in the 1000 mg/kg bw/day group. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no abnormalities attributable to the test substance treatment at the end of the treatment or recovery periods.
A high value of total bilirubin was noted in females in the 200 mg/kg bw/day group; however, similar change was not noted in the 1000 mg/kg bw/day group, and therefore, this change was not considered to be treatment-related. Moreover, low vales of albumin and sodium were noted in males in the 1000 mg/kg bw/daygroup, and a high value of potassium was noted in males in the 200 and 1000 mg/kg bw/day groups; however, these changes were not considered to be treatment-related because these were slight and within the physiological range, and were not noted at the end of the treatment period. - Endocrine findings:
- not examined
- Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no abnormalities attributable to the test substance treatment at the end of the treatment period.
A high value of protein was noted in males in the 8, 40, and 1000 mg/kg bw/day groups; however it was not considered to be treatment-related because it was within the physiological range. - Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no significant differences between the control and test substance-treated groups in any organs.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no abnormalities attributable to the test substance treatment.
The following changes were noted; however, since these changes were observed spontaneously in this strain, they were not considered to be treatment-related: erythrocytic extramedullary hematopoiesis in the spleen, eosinophilic inclusion body in the hepatocyte, fatty change of the periportal hepatocyte, microgranuloma and focal necrosis in the liver, cyst and hyaline droplet in the proximal tubular epithelium in the kidney. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no abnormalities attributable to the test substance treatment. Hepatodiaphragmatic nodule in the liver and cyst in the kidney were noted in the test substance-treated group; however, these changes were not considered to be treatment-related because these were often observed as spontaneous changes in this strain, and there was no dose-relation.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
Effect levels
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- serum/plasma biochemistry
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The no-observed-effect-level (NOEL) of Reinblau RLW was considered to be 1000 mg/kg bw/day for male and female rats.
- Executive summary:
In a subacute toxicity study performed similarly to OECD TG 407 and in compliance with GLP, Reinblau RLW suspended in CMC-Na solutions was administered to Crl: CD SD IGS rats (6/sex/dose in the control and high dose groups; 6/sex/dose in the other groups) by gavage at dose levels of 0, 8, 40, 200 and 1000 mg/kg bw/day. In addition, 6 rats/sex/dose in the control and 1000 mg/kg bw/day groups were subjected to a recovery period of 14 days.
There were no test substance-related toxic changes in clinical sign, body weight, food consumption, hematology, blood chemistry, urinalysis, organ weight, necropsy, or histopathology.
Therefore, the no-observed-effect-level (NOEL) of Reinblau RLW was considered to be 1000 mg/kg bw/day for male and female rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.